Key Highlights

  • The Top Line reached $1,350.2 million, a 6.0% advance that becomes 7.6% after excluding currency effects.
  • Attributable profit climbed 36.1%, reaching $58.8 million, which equals $0.55 a diluted share.
  • Adjusted EBITDA reached $182 million, equating to a 13.5% margin, 70 basis points better than last year.
  • India sales surged $87 million, or 39%, while EMEA sales slipped 4.9%.
  • The full-year reported sales growth range was lifted to 4.9% through 5.9%.

Volume-Led Sales Advance of 8.6% Paired With India's Surge

Herbalife (NYSE:HLF) reported on Nov 2, 2026 for the quarter that ended Sep 30, 2026. Its sales came to $1,350.2 million, which was $76.5 million or 6.0% above the prior-year period. Measured in local currency, sales expanded 7.6%, comfortably beating the company's 1.5% to 5.5% guided band. This marked a fifth straight quarter of growth.

The company's offerings span nutrition, weight management and wellness, distributed by independent sellers, with more than 3 million entrepreneurs active across over 90 markets. Volume contributed 8.6% growth and pricing added 2.8%, but sales mix took away 3.8% and currency cut 1.6%.

India led the expansion, adding $87 million, a 39% rise, on nearly 50% higher volume. Latin America grew 9.0% and North America 1.7%, while EMEA dropped 4.9% as volume fell 10.2%.

Net Income Advances 36.1% as Lower Interest Costs Absorb Higher Overheads

Attributable profit for Herbalife totaled $58.8 million, a $0.55 per-share figure on a diluted basis, and a $15.6 million increase on the prior year. Adjusted diluted EPS reached $0.64, a $0.14 improvement, though a $0.06 currency drag was included. Gross Profit increased $54.6 million, and net interest expense declined $19.1 million following the April 2026 refinancing.

Higher selling costs of $22.8 million and G&A up $19.1 million, driven by labor, benefits and non-income taxes (chiefly India GST), offset part of those gains. Taxes on income went up by $17.8 million.

The $182 million adjusted EBITDA figure topped guidance, which had been $160 million to $180 million. Gross Margin slipped 40 basis points to 77.3%, as country mix plus Manufacturing and sourcing expenses outweighed price increases.

Nine-Month Operating Cash of $298 Million and a Newly Approved $250 Million Program

Operating cash inflow exceeded $151 million in the quarter and reached $298 million across nine months, a 27% gain. Cash stood at $409 million at the end of September after $88 million of Debt repayment, while $50 million remained drawn on the revolver.

Net Leverage fell to 2.0x from 2.2x by the end of the second quarter. A newly authorized $250 million repurchase initiative begins in the fourth quarter.

Under the interim chief executive, management set three priorities: building a dedicated Nutrition Club organization, beginning the rollout of a shared technology platform in Q1 2027, and broadening the Bioniq brand.

Softer Q4 Profit Expectations Sit Alongside a Higher Annual Sales Range

For the final quarter, Herbalife projects reported net sales growth from 0.5% up to 4.5%, plus adjusted EBITDA between $145 million and $165 million, which sits beneath the third-quarter level. Leadership expects margin gains to build more slowly and is watching input prices. Some benefit that landed in Q3 from distributor event timing will shift into the fourth quarter this year.

On a reported basis, annual sales growth is now expected between 4.9% and 5.9%. The adjusted EBITDA range of $670 million to $690 million stays where it was. The CFO intends to present three-year margin objectives on the fourth-quarter call.